Trials / Completed
CompletedNCT02147158
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 432 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ulipristal acetate (UPA) | Ulipristal acetate (UPA) tablet. |
| DRUG | Placebo | Matching placebo tablet. |
Timeline
- Start date
- 2014-01-29
- Primary completion
- 2016-11-24
- Completion
- 2016-11-24
- First posted
- 2014-05-26
- Last updated
- 2019-06-04
- Results posted
- 2019-06-04
Locations
63 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02147158. Inclusion in this directory is not an endorsement.